Multiple sclerosis (MS) remains a highly unpredictable disease. Many hope that fluid biomarkers may contribute to better stratification of disease, aiding the personalisation of treatment decisions, ultimately improving patient outcomes. The objective of this study was to evaluate the predictive value of CSF brain-specific proteins from early in the disease course of MS on long term clinical outcomes. In this study, 34 MS patients had their CSF collected and stored within 5 years of disease onset and were then followed clinically for at least 15 years. CSF concentrations of 64 brain-specific proteins were analyzed in the 34 patient CSF, as well as 19 age and sex-matched controls, using a targeted liquid-chromatography tandem mass spectrometry approach. We identified six CSF brain-specific proteins that significantly differentiated MS from controls (p < 0.05) and nine proteins that could predict disease course over the next decade. CAMK2A emerged as a biomarker candidate that could discriminate between MS and controls and could predict long-term disease progression. Targeted approaches to identify and quantify biomarkers associated with MS in the CSF may inform on long term MS outcomes. CAMK2A may be one of several candidates, warranting further exploration.

中文翻译：

---

基线脑脊液 camk2a 水平可预测多发性硬化症的长期进展

多发性硬化症（MS）仍然是一种高度不可预测的疾病。许多人希望液体生物标志物有助于更好地对疾病进行分层，帮助个性化治疗决策，最终改善患者的治疗结果。本研究的目的是评估多发性硬化症病程早期脑脊液脑特异性蛋白对长期临床结果的预测价值。在这项研究中，34 名多发性硬化症患者在发病后 5 年内收集并储存了脑脊液，然后进行了至少 15 年的临床随访。使用靶向液相色谱串联质谱方法，分析了 34 名患者 CSF 以及 19 名年龄和性别匹配的对照中 64 种脑特异性蛋白质的 CSF 浓度。我们鉴定了六种脑脊液大脑特异性蛋白质，可将多发性硬化症与对照组显着区分开来（p < 0.05），以及九种可预测未来十年疾病进程的蛋白质。CAMK2A 作为一种候选生物标志物出现，可以区分 MS 和对照，并可以预测长期疾病进展。有针对性地识别和量化脑脊液中与多发性硬化症相关的生物标志物的方法可能有助于了解多发性硬化症的长期结果。CAMK2A 可能是几个候选者之一，值得进一步探索。